Oral GLP-1 induces weight loss of up to 12.4% at 72 weeks for adults with obesity

Key takeaways:

Adults with overweight or obesity lost significantly more weight at 72 weeks with the oral GLP-1 orforglipron vs. placebo.

The drug was tied to improvements in systolic BP, triglycerides and non-HDL cholesterol.

An oral GLP-1 induced significantly greater weight loss than placebo for adults with obesity or overweight plus one weight-related comorbidity, according to data from the ATTAIN-1 trial.

Orforglipron (Eli Lilly) is a once-daily oral nonpeptide GLP-1 under investigation for the treatment of obesity and type 2 diabetes. Sean Wharton, MD, PharmD, medical director of the Wharton Medical Clinic and assistant professor at the University of Toronto, said the drug differs from other oral GLP-1s in that it uses a small molecule that favors activation of the cyclic ade